TY - JOUR
T1 - A new therapy paradigm for prostate cancer founded on clinical Observations
AU - Efstathiou, Eleni
AU - Logothetis, Christopher J.
PY - 2010/2/15
Y1 - 2010/2/15
N2 - Efficacy equivalent to that reported in other common adult solid tumors considered to be chemotherapy-sensitive has been reported with Docetaxel in patients with castrate-resistant prostate cancer. However, in contrast to other cancers, the expected increase in efficacy with the use of chemotherapy in earlier disease states has not been reported to date in prostate cancer. On the basis of these observations, we speculated that the therapy development paradigm used successfully in other cancers may not apply to the majority of prostate cancers. Several lines of supporting clinical and experimental observations implicate the tumor microenvironment in prostate carcinogenesis and resistance to therapy. We conclude that a foundation to guide the development of therapy for prostate cancer is required. The therapy paradigm we propose accounts for the central role of the tumor microenvironment in bone and, if correct, will lead to microenvironmenttargeted therapy.
AB - Efficacy equivalent to that reported in other common adult solid tumors considered to be chemotherapy-sensitive has been reported with Docetaxel in patients with castrate-resistant prostate cancer. However, in contrast to other cancers, the expected increase in efficacy with the use of chemotherapy in earlier disease states has not been reported to date in prostate cancer. On the basis of these observations, we speculated that the therapy development paradigm used successfully in other cancers may not apply to the majority of prostate cancers. Several lines of supporting clinical and experimental observations implicate the tumor microenvironment in prostate carcinogenesis and resistance to therapy. We conclude that a foundation to guide the development of therapy for prostate cancer is required. The therapy paradigm we propose accounts for the central role of the tumor microenvironment in bone and, if correct, will lead to microenvironmenttargeted therapy.
UR - http://www.scopus.com/inward/record.url?scp=76749108148&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=76749108148&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-09-1215
DO - 10.1158/1078-0432.CCR-09-1215
M3 - Review article
C2 - 20145177
AN - SCOPUS:76749108148
SN - 1078-0432
VL - 16
SP - 1100
EP - 1107
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 4
ER -